Mylan Inc. (Nasdaq: MYL) announced yesterday, in its financial report for 2011, that it plans to launch a generic version of Copaxone, Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) intravenous treatment for multiple sclerosis, in the second half of 2013. Mylan added that patent litigation and US Food and Drug Administration (FDA) approval of its drug are pending. Mylan chairman Robert Coury said, “We expect that 2012 will be yet another year of exciting growth for Mylan, as will 2013, as we remain committed to our adjusted earnings per share target of $2.75. Our confidence comes as a result of the last several years of hard work and execution, while at the same time delivering strong results for the past 16 quarters.”
